Genomic and Proteomic Biomarkers for Cystic Fibrosis

Cystic fibrosis is a common lethal genetic disease which is manifest by intrinsic hyperactivation of proinflammatory signaling pathways in the lung. However, the mechanism linking the CFTR mutation to inflammatory disease is still not known. Researchers from Johns Hopkins and The Uniformed Services University of Health have identified nucleic acid and protein markers whose abundance and synthesis is significantly increased in cystic fibrosis patients and cell lines. In addition, an antibody microarray for serum proteomics and brush border biopsy-derived biosynthetic proteins has been developed. Description (Set) Proposed Use (Set) This technology provides new biomarkers for cystic fibrosis. These biomarkers may be used for disease diagnosis, monitoring disease progression and the development of new therapeutics

Inventor(s): Zeitlin, Pam

Type of Offer: Licensing



« More Diagnostic Patents

---